Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Buy" from Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been given a consensus rating of "Buy" by the five analysts that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $32.80.

A number of brokerages have issued reports on AARD. HC Wainwright began coverage on Aardvark Therapeutics in a research note on Monday, June 30th. They set a "buy" rating and a $40.00 price target for the company. Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Finally, Wall Street Zen lowered Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th.

Aardvark Therapeutics Stock Performance

NASDAQ AARD traded up $0.04 on Tuesday, reaching $9.77. 77,987 shares of the stock traded hands, compared to its average volume of 50,864. The stock's fifty day moving average price is $12.37. Aardvark Therapeutics has a 12 month low of $4.88 and a 12 month high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.14).

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth $42,000. Bank of America Corp DE boosted its stake in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock worth $108,000 after acquiring an additional 3,369 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Aardvark Therapeutics in the second quarter worth $99,000. Walleye Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the first quarter worth $88,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Aardvark Therapeutics during the first quarter valued at $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.